Pheniramine

Summary

Pheniramine (CHEMBL1193) is an approved small molecule (ATC D04AA16); indicated across 3 conditions including allergic disease and common cold.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: D04AA16 (+1 more)
• Indications: 3 conditions
• Chemistry: 240.34 Da · C16H20N2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1193
Name	Pheniramine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	4761
ATC	D04AA16, R06AB05
Molecular formula	C16H20N2
Molecular weight	240.34
InChIKey	IJHNSHDBIRRJRN-UHFFFAOYSA-N

SMILES: CN(C)CCC(C1=CC=CC=C1)C2=CC=CC=N2

IUPAC name: N,N-dimethyl-3-phenyl-3-pyridin-2-ylpropan-1-amine

Also known as: Feniramina, NSC-47965, Pheniramine, Propheniramine, Prophenpyridamine, Pyriton, Tripoton, SID90341510, PHENIRAMINE, pheniramine

Parent form; salt/anhydrous children: CHEMBL1653, CHEMBL1580221, CHEMBL1596440

Patent coverage: 3,041 distinct patent families (11,218 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 11,216 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 4 (assay-derived). Sample: Sodium channel alpha subunits; brain (Types I, II, III), Muscarinic acetylcholine receptor M2, Sodium-dependent noradrenaline transporter, Sodium-dependent serotonin transporter.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 4 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
SLC6A4	5.1	AC50	7980	nM	CHEMBL_ACT_25151027

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
allergic disease	4	MONDO:0005271	MONDO:0005271
common cold	3	MONDO:0005709	EFO:0007214

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).